Search Results

RefleXion Medical, Inc. announced that the Centers for Medicare and Medicaid Services has established a national payment rate for RefleXion’s SCINTIX® biology-guided radiotherapy using CMS’ New Technology Ambulatory Payment Classification pathway.

RefleXion Medical, Inc. today announced that Todd Powell, president and chief executive officer, Sam Mazin, Ph.D., founder and chief technology officer, and Sean Shirvani, M.D., chief medical officer will present an overview of the company and its breakthrough SCINTIX biology-guided radiotherapy at the Jeffries Global Healthcare Conference on Wednesday, June 5 at 8:30 a.m. EDT.

RefleXion Medical, Inc. and Limbus AI, Inc. announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.

RefleXion Medical, a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX™ biology-guided radiotherapy on the RefleXion® X1 machine at the Stanford Medicine Cancer Center.

RefleXion Medical, a therapeutic oncology company, today announced the initial closing of a $105M equity raise, led by The Rise Fund, TPG’s multi-sector global impact investing strategy.

RefleXion® Medical, a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831).

RefleXion Medical, a therapeutic oncology company, today announced that researchers from multiple clinical programs will present new scientific evidence in 28 oral, panel, and poster presentations validating the efficacy and feasibility of the RefleXion® X1 machine with SCINTIX™ biology-guided radiotherapy at the 2023 American Association of Physicists in Medicine (AAPM) Annual Meeting in Houston, July 23-26.

RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX™ biology-guided radiotherapy.

RefleXion Medical, Inc. today announced that results of a prospective investigator-initiated clinical imaging study conducted on its X1 platform by City of Hope using positron emission tomography (PET) were presented on June 24 during an oral session at the Society of Nuclear Medicine and Medical Imaging (SNMMI) annual meeting in Chicago.